SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential inclusion in the Russell 1000 index, driving significant options activity and ongoing conflict between bullish sentiment and short sellers. Community members are actively debating the likelihood of index inclusion while tracking potential catalysts regarding commercialization and regulatory updates.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors speculate on a potential buyout following executive severance changes and the highly anticipated upcoming Phase 3 trial data readout. The community is heavily focused on a potential short squeeze, noting record short interest and soaring borrow costs that are fueling significant upward momentum.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is experiencing intense volatility driven by speculative frenzy and heavy institutional interest surrounding the memory and storage supercycle tied to AI infrastructure demand. The community is sharply divided, with bulls betting on sustained sector growth and potential price target upgrades, while bears warn of a classic bubble cycle and imminent overextension.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as retail investors voice frustration over persistent, low-volume price swings that many describe as market manipulation. Community discussion remains heavily focused on the stock's volatility and its challenging technical performance compared to broader market trends.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether the stock is a deep-value opportunity at multi-year lows or a structural value trap heading into earnings. The community remains sharply divided, with bulls pointing to the company's iconic brand status and potential tariff refunds, while bears express skepticism over slowing China sales, heavy competition, and recent management changes.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense community focus as investors prepare for an upcoming AGM where the redomiciling plan to the U.S. is expected to be a primary catalyst for institutional interest. Market participants are actively debating the company's manufacturing ramp-up and recent strategic partnership developments while balancing volatility driven by broader sector trends and pending class-action deadlines.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors closely monitor a pivotal court hearing regarding commercial distribution rights ahead of the expected late-August FDA decision for its Duchenne muscular dystrophy therapy, Deramiocel. The community is actively debating the legal battle with Nippon Shinyaku while expressing strong optimism about the therapy's clinical data and potential for broad label approval.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending due to the volatility surrounding its all-stock acquisition of Synaptics, as market participants weigh the potential for long-term expansion into edge and physical AI against immediate concerns regarding equity dilution. While the stock has faced sharp downward pressure following the deal announcement, community discussion is divided between those bracing for further technical retesting and bulls viewing the current price levels as an attractive entry point for a long-term strategic play.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as retail investors rally to trigger a potential short squeeze, fueled by community efforts to lock up the float and push the price above key technical levels. Investors are actively discussing the stock's undervaluation, high dividend yield, and potential for institutional buyouts as catalysts to drive a sustained upward move.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently facing significant selling pressure and volatility, with the community actively debating whether the stock is undergoing market manipulation or reflecting genuine concerns regarding high debt levels and operational management. Investors are closely monitoring potential developments regarding a partnership with POSCO and the broader impact of hot-rolled coil steel prices on future earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know

Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Are Medical Stocks Lagging  Atea Pharmaceuticals (AVIR) This Year?

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround 

Atea Pharmaceuticals (AVIR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Tuesday

Atea Pharmaceuticals (NASDAQ:AVIR) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-atea-pharmaceuticals-inc-stock...

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 1.6% - Still a Buy?

Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 1.6% - Time to Buy...

Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price Up 5.9% - Here's Why

Atea Pharmaceuticals (NASDAQ:AVIR) Shares Up 5.9% - Time to Buy...

Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why

Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 1-Year High - What's Next...

Atea Pharmaceuticals Q4 Earnings Call Highlights

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its...

Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus...

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Atea Pharmaceuticals Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.56	--	--	N/A
Q1 '26	-$0.56	-$0.57	-2.70%	MISSED
Q4 '25	-$0.49	-$0.57	-17.53%	MISSED
Q3 '25	-$0.41	-$0.53	-27.71%	MISSED
Q2 '25	-$0.41	-$0.44	-6.02%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

AVIRAtea Pharmaceuticals Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest AVIR News